Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | STK10 | O94804 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21814162 | 1.00 | NPC1 (0.48) | NPC1RAB9AALOX12ALOX15MAPKAPK2 | |
| SCHEMBL7628174 | 0.86 | ALOX12 (0.50) | NPC1RAB9AALOX12ALOX15MAPKAPK2 | |
| SCHEMBL15948901 | 0.86 | ALOX12 (0.50) | NPC1RAB9AALOX12ALOX15MAPKAPK2 | |
| SCHEMBL15946929 | 0.84 | ALOX12 (0.52) | NPC1RAB9AALOX12ALOX15MAPKAPK2 | |
| SCHEMBL29391897 | 0.84 | ALOX12 (0.46) | NPC1RAB9AALOX12ALOX15MAPKAPK2 | |
| SCHEMBL19323073 | 0.81 | ALOX12 (0.50) | NPC1RAB9AALOX12ALOX15MAPKAPK2 | |
| SCHEMBL19318589 | 0.81 | ALOX12 (0.47) | NPC1RAB9AALOX12ALOX15MAPKAPK2 | |
| SCHEMBL3661276 | 0.81 | ALOX12 (0.50) | NPC1RAB9AALOX12ALOX15MAPKAPK2 | |
| SCHEMBL19318545 | 0.81 | ALOX12 (0.47) | NPC1RAB9AALOX12ALOX15MAPKAPK2 | |
| SCHEMBL19324441 | 0.81 | ALOX12 (0.50) | NPC1RAB9AALOX12ALOX15MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3861000-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | Genzyme Corporation (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072504-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-7598258-B2 | N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1535910-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | NPC1 95/4885RAB9A 2611/4885ALOX12 1164/4885 |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | CSF3R, CSF1R, MSR1 | NPC1 3079/4885RAB9A 1608/4885ALOX12 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.